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Background: Accelerated cell cycle progression is the common feature of most cancers. MiRNAs can act as
oncogenes or tumor suppressors by directly modulating cell cycle machinery. It has been shown that miR-188 is
upregulated in UVB-irradiated mouse skin and human nasopharyngeal carcinoma CNE cells under hypoxic stress.
However, little is known about the function of miR-188 in cell proliferation and growth control.
Results: Overexpression of miR-188 inhibits cell proliferation, tumor colony formation and G1/S cell cycle transition
in human nasopharyngeal carcinoma CNE cells. Using bioinformatics approach, we identify a series of genes
regulating G1/S transition as putative miR-188 targets. MiR-188 inhibits both mRNA and protein expression of
CCND1, CCND3, CCNE1, CCNA2, CDK4 and CDK2, suppresses Rb phosphorylation and downregulates E2F transcriptional
activity. The expression level of miR-188 also inversely correlates with the expression of miR-188 targets in human
nasopharyngeal carcinoma (NPC) tissues. Moreover, studies in xenograft mouse model reveal that miR-188 is capable of
inhibiting tumor initiation and progression by suppressing target genes expression and Rb phosphorylation.
Conclusions: This study demonstrates that miR-188 exerts anticancer effects, via downregulation of multiple G1/S
related cyclin/CDKs and Rb/E2F signaling pathway.
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MicroRNAs (miRNAs) are a class of small non-coding
RNAs that negatively regulate gene expression at the post-
transcriptional level [1]. MiRNAs are important regulators
of various biological and pathological processes, including
cell proliferation, differentiation, apoptosis, metabolism
and cancer [2-11]. As “micromanagers” of gene expres-
sion, miRNAs often have subtle influence on one single
target. A variety of studies indicate that an individual
miRNA may perform its function through targeting mul-
tiple components in one signaling pathway [9,12,13]. In
addition, multiple miRNAs can act on the same signaling
pathway or biological process [14-17].* Correspondence: xu.naihan@sz.tsinghua.edu.cn; zhangyo@sz.tsinghua.edu.cn
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unless otherwise stated.Cell cycle progression is directly driven by a series of
heterodimers formed by cyclins and cyclin-dependent ki-
nases (CDKs) [18]. The decision for a cell to enter S
phase is tightly controlled by cyclin D/CDK4/6 and cyc-
lin E/CDK2 complexes, followed by cyclin A/CDK2
throughout S phase [18-20]. In mammalian cells, G1 to S
phase progression is also regulated by the Retinoblast-
oma protein (Rb). Rb is a tumor suppressor protein that
plays a pivotal role in the negative control of cell cycle
and in tumor progression [21,22]. The Rb protein in-
hibits the expression of genes required for entry into S
phase by sequestering the E2F family of transcription
factors [23,24]. During G1 phase of the cell cycle, Rb
binds to E2F-DP1 and inhibits downstream transcrip-
tion. When it is time for a cell to enter S phase, the in-
activating phosphorylation of Rb by the G1/S CDKs
results in the release of Rb from E2F-DP1 and allows for
the activation of E2F target genes that are responsible
for facilitating G1/S transition and S phase progression.
Several lines of evidence indicate that miRNAs are im-
portant cell cycle regulators. Some miRNAs regulate cell. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of cyclin/CDK complexes. For instance, miR-15/16 fam-
ily induces cell cycle arrest by simultaneously targeting
multiple cyclins that regulate G1/S transition; these in-
clude CCND3, CCNE1 and CDK6 [25,26]. CDK6 and
CCND1 are also regulated by miR-34a, which induces a
significant G1 cell cycle arrest in human lung carcinoma
A549 cells [27]. CDK6 is targeted by miR-137 and miR-
124a. The expression of both of these miRNAs is epigenet-
ically silenced by hypermethylation in some human cancers
[28-30]. Transfection of miR-137 or miR-124a causes G1
arrest in glioblastoma multiforme cells [31]. In addition,
miR-206 suppresses CCND1 expression and plays a tumor
suppressive function in skeletal muscle differentiation
[32]. Besides cyclin/CDK complexes, miRNAs also modu-
late cell proliferation through interacting with critical cell
cycle regulators that are involved in G1/S and G2/M tran-
sitions, such as Cip/Kip and INK4a/ARF family members,
E2F family transcription factors, Cdc25, Wee1 and p53,
etc. [33]. Therefore, better understanding the roles of
miRNAs in cell proliferation and cell cycle checkpoints
may shed light on cancer pathogenesis and lead to rational
development of new types of cancer therapy.
MiR-188, a miRNA located on the X chromosome in
humans, was first identified in 2003 [34]. It has been re-
ported that miR-188 is upregulated by the induction of
long-term potentiation (LTP) and it serves to fine-tune
synaptic plasticity by targeting neuropilin-2 (Nrp-2) ex-
pression in the nervous system [35]. Recent studies also
show that miR-188 is upregulated in UVB-irradiated
mouse skin and human nasopharyngeal carcinoma CNE
cells under hypoxic stress [36,37]. However, little is known
about the function of miR-188 on cell proliferation and
cell cycle regulation. Here, we report that miR-188 is
a potent tumor suppressor in human nasopharyngeal
carcinoma cells. Overexpression of miR-188 inhibits cell
proliferation and G1/S transition by directly targeting
the expression of multiple cyclin/CDKs complexes, in-
cluding CCND1, CCND3, CCNE1, CCNA2, CDK2 and
CDK4. MiR-188 also suppresses Rb phosphorylation and
E2F transcriptional activity. Further study from xenograft
mouse model shows that miR-188 has anti-cancer poten-
tial through suppressing tumor initiation and progression.
Taken together, our data highlight the anti-cancer poten-
tial of miR-188 and provide a novel mechanism whereby
miR-188 controls cell cycle progression via downregula-
tion of multiple cyclin/CDK complexes involved in G1/S
transition.
Results
Overexpression of miR-188 suppresses cancer cell
proliferation
To characterize the function of miR-188 on cancer cell
proliferation, miR-188 mimics or negative control (miR-NC) were transiently transfected into human nasopha-
ryngeal cancer CNE cells. Strikingly, we observed that
overexpression of miR-188 attenuated cell proliferation
in CNE cells (Figure 1A and B). The effect of miR-188
on cell proliferation was also evaluated using colony for-
mation assay. MiR-188 transfected cells formed signifi-
cantly less colonies than those transfected with the
negative control (Figure 1C and D).
By quantifying the level of miR-188 in CNE cells, we
found that the expression of miR-188 increased by nearly
1000 folds after transient transfection of miRNA mimics,
which is far beyond the level of endogenous miR-188
(Additional file 1: Figure S1A). To create a scenario closer
in resemblance to the normal physiological state, we gen-
erated CNE cells that stably expressed miR-188 to ascer-
tain its effect on cell proliferation. We selected two stable
clones in which the expression of miR-188 was nearly 4
folds higher than the negative control (Additional file 1:
Figure S1B). Although, there was no significant difference
among the colonies between each plate, the colony size of
cells stably expressed miR-188 was much smaller than that
of the control (Figure 1E). Similar to transiently trans-
fected cells, cell proliferation rate was significantly reduced
in the miR-188 stably expressed clones (Figure 1F). Our
data indicate that miR-188 expressed cells have slower
growth and cell proliferate rate.
MiR-188 targets multiple cyclin/CDKs involved in G1/S
transition
To investigate the potential targets of miR-188, we
searched the genome using miRNA target prediction
algorithms, Targetscan and Findtar. We found that 2214
genes contain potential miR-188 target sites. We then
employed DAVID Bioinformatics Resources (http://
david.abcc.ncifcrf.gov/home.jsp) for functional annota-
tion clustering and enrichment scoring [38,39]. Accord-
ing to pathway annotation summary, the KEGG (Kyoto
Encyclopedia of Genes and Genomes) pathway was clas-
sified as containing most of the genes identified by
DAVID as potential targets of miR-188 (Figure 1G left
panel). The KEGG contains 26 signaling pathways, among
these, MAPK signaling pathway (p value: 1.08 × 10−5),
ErbB signaling pathway (p value: 3.57 × 10−4), axon guid-
ance (p value: 5.16 × 10−3) and cell cycle (p value: 7.20 ×
10−3) were the four pathways most significantly associated
with miR-188 according to p values (Figure 1G middle
panel, Additional file 2: Table S1). Since cell growth and
cell proliferation are highly associated with cell cycle regu-
lation, we analyzed 23 of the genes in the cell cycle path-
way and identified a series of cyclins and CDKs involved
in G1/S transition that could be potential miR-188 targets
(Figure 1G right panel).
Using miRNA target prediction algorithms Findtar, we
found that six G1/S related genes, including CCND1,
Figure 1 MiR-188 inhibits cell proliferation and tumor colony formation. (A) Overexpression of miR-188 inhibits cell growth in CNE cells. CNE
cells were transfected with miR-188 or miR-NC for 72 h, the representative phase contrast images were shown. Scar bar: 250 μm. (B) Overexpression of
miR-188 inhibits cell proliferation. Equal amounts of CNE cells were transfected with miR-188 or miR-NC, cell proliferation was monitored at indicated
time points. Data presented are means ± SD from three independent experiments (Student t test, *p < 0.05, **p < 0.01). (C) Clonogenic assay of CNE
cells transfected with miR-NC or miR-188. Cells were cultured for 10 days and stained with Crystal Violet. (D) The number of colonies were quantified
and calculated as means ± SD of three independent experiments (Student t test, ***p < 0.001). (E) Clonogenic assay of CNE cells stably expressing
miR-NC or miR-188. (F) Stable transfection of miR-188 inhibits cell proliferation. Equal amounts of miR-NC or miR-188 stable cell lines were cultured for
4 days, cell proliferation was monitored at indicated time points. Data shown are means ± SD from three independent experiments (Student t test,
*p < 0.05, **p < 0.01, ***p < 0.001). (G) The functional association of miR-188 target genes. DAVID Functional Annotation tool was used for analysis of
potential targets predicted from Targetscan and Findtar. A series of cell cycle related genes were potential targets of miR-188.
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miR-188 response elements in their 3′UTRs (Figure 2A).
To validate, we overexpressed miR-188 in CNE cells, then
harvested cells for mRNA and protein expression level
measurements for these six genes. Results from qRT-PCR
showed that overexpression of miR-188 resulted in 30-
50% reduction in transcript abundance for CCND1,
CCNA2, CCND3, CCNE1, CDK2 and CDK4 (Figure 2B).Similarly, western blot experiments demonstrated that
the protein levels of these genes were significantly sup-
pressed to various degrees by miR-188 overexpression
in both transiently and stably transfected cells (Figure 2C,
Additional file 3: Figure S2A, B).
To test whether silencing endogenous miR-188 would
affect target gene expression, we transfected cells with
miR-188 antisense oligonucleotides (ant-188). Compared
Figure 2 (See legend on next page.)
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Figure 2 MiR-188 downregulates multiple genes related to G1/S transition. (A) CCND1, CCND3, CDK4, CCNA2, CDK2 and CCNE1 are predicted
to be miR-188 target genes. (B) qRT-PCR analysis of mRNA expression levels of miR-188 targets in CNE cells transfected with miR-NC or miR-188. Data
are presented as means ± SD of three independent experiments (Student t test, *p < 0.05, **p < 0.01, ***p < 0.001). (C) Overexpression of miR-188
downregulates the protein expression of cyclin E1, CDK2, cyclin A2, cyclin D1, cyclin D3 and CDK4. (C1, stable clone 1; C2, stable clone 2). All
western blots were performed at least three times. (D) Western blot analysis of cyclin E1, CDK2, cyclin A2, cyclin D1, cyclin D3 and GAPDH in
CNE cells transfected with Ant-188 or Ant-NC. All western blots performed at least three times. (E) Inverse correlation between miR-188 and its
targets in NPC tissues. The relative levels of miR-188, CCND1, CCND3, CDK4, CCNA2, CDK2 and CCNE1 were quantified using qRT-PCR.
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amounts of CCND1, CCNA2, CCND3, CCNE1, CDK2
and CDK4 proteins increased slightly when endogenous
miR-188 expression was silenced (Figure 2D, Additional
file 3: Figure S2C). Therefore, these results suggest that
miR-188 inhibits cell proliferation, potentially via down-
regulation of multiple cyclin/CDK complexes involved in
G1/S transition.
Inverse correlation of miR-188 and its target genes in
NPC tissues
To define the clinical relevance of our findings that miR-
188 suppressed the expression of G1/S related cyclin/
CDKs, we showed that miR-188 expression was possibly
associated with human nasopharyngeal carcinoma.
Namely, we examined the expression of miR-188 and its
target genes in NPC tissues using qRT-PCR, and an
inverse correlation between miR-188 and CCND1,
CCNA2, CCND3, CCNE1, CDK2 or CDK4 expression
was identified in patient samples (Figure 2E). Thus, the
in vitro and in vivo results further demonstrate that
miR-188 targets the expression of multiple G1/S related
cyclin/CDKs.
MiR-188 delays G1/S cell cycle progression
Having identified the potential targets of miR-188, we
then wanted to determine the role of miR-188 on cell
cycle progression, especially on G1/S transition. CNE
cells transfected with miR-188 or miR-NC were synchro-
nized at G1/S boundary by treatment with hydroxyurea.
At 6 hours after release from hydroxyurea, the vast
majority of control cells were in S and G2/M phase
(Figure 3A). The G1 cell population was bigger in miR-
188 transfected CNE cells (21.7 ± 1.38%) than that in
control cells (14.6 ± 0.95%) (Figure 3A). Similar results
were obtained from miR-188 stably overexpressed cells
(Additional file 4: Figure S3A).
One feature of G1/S transition is the beginning of gen-
omic DNA synthesis. Chemicals, such as BrdU or EdU,
can be inserted into newly synthesized DNA to allow for
visualization of the chromosomes. A precise evaluation
of cell proliferation can be performed by measuring
BrdU or EdU incorporation in proliferating cells during
DNA synthesis. First, we performed cell proliferation
ELISA BrdU assay. Namely, CNE cells were synchronizedat G1 phase by treatment with hydroxyurea. Subsequently,
they were released and labeled with BrdU for 2 hours.
The incorporation of BrdU was then determined by meas-
uring chemiluminescence. There was a significant reduc-
tion of BrdU incorporation in miR-188 transfected cells
(Figure 3B). This observation was confirmed by EdU
image assay. The incorporation of EdU in miR-188 trans-
fected cells was significantly less than that of control cells
(Figure 3C and D). Together, these results demonstrate
that miR-188 suppresses cell proliferation mainly by inter-
rupting G1/S cell cycle progression.
MiR-188 suppresses Rb phosphorylation and E2F
transcriptional activity
E2F activity is crucial for G1/S transition and DNA repli-
cation in mammalian cells. The tumor suppressor Rb
is the primary negative regulator of E2F. Disruption of
Rb/E2F interaction is achieved through CDK-mediated
phosphorylation of Rb. The initial phosphorylation is
performed by Cyclin D/CDK4/CDK6 and followed by
additional phosphorylation by Cyclin E/CDK2. Since we
have shown that miR-188 downregulates the expression
of Cyclin D/CDK4 and Cyclin E/CDK2 complexes, we
wanted to ask whether overexpression of miR-188 would
have an impact on Rb phosphorylation. The phosphoryl-
ation status of Rb at ser780 and ser811 was detected
using western blot. We found that miR-188 suppressed
CDK-mediated Rb phosphorylation since silencing en-
dogenous miR-188 with ant-188 increased the amount
of Rb phosophorylation while miR-188 transfected
cells showed less Rb phosphorylation (Figure 3E and F,
Additional file 4: Figure S3B). Similarly, Rb phosphoryl-
ation at S811 and S780 residues were significantly reduced
in CNE cells stably expressing miR-188 (Additional file 4:
Figure S3C, D). These results indicate that miR-188 also
plays an important role on Rb phosphorylation.
E2F acts as a transcription factor in the nucleus and
activates down-stream gene expression to drive cell cycle
progression. A reduction of Rb phosphorylation would
affect its dissociation from E2F and therefore, affect E2F
activation. Thus, we speculated that overexpression of
miR-188 would lead to a downregulation of E2F tran-
scriptional activity. Using a pE2F-TA-Luc plasmid that
contains four copies of E2F binding elements, we
showed that enforced expression of miR-188 remarkably
Figure 3 (See legend on next page.)
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Figure 3 MiR-188 arrests cell cycle at G1/S transition through negative regulation of Rb-E2F axis. (A) CNE cells transfected with miR-188
or miR-NC were synchronized at G1/S boundary by hydroxyurea treatment. Cells were released from hydroxyurea block for 6 h, fixed and stained
with propidium iodide (PI) for flow cytometry analysis. (B) miR-188 inhibits BrdU incorporation. BrdU Elisa Assay of CNE cells released from hydroxyurea
block for 4 h. The BrdU incorporation was quantified by measuring the chemiluminescence. Data shown as means ± SD from three independent
experiments (Student t test, ***p < 0.001). (C) Confocal immunofluorescence analysis of CNE cells stained with EdU (green) and DAPI (blue). Scar
bar: 10 μm. (D) Quantification of EdU positive cells in CNE cells transfected with miR-188 or miR-NC released from hydroxyurea block for 2 h.
Data are presented as means ± SD from three independent experiments (Student t test, **p < 0.01). (E) Immunoblot analysis of phosphorylated
and total Rb expression in CNE cells transfected with miR-NC, miR-188, (F) Ant-NC or Ant-188 respectively. GAPDH were used as internal control.
(G) E2F promoter activity was determined directly by use of a pE2F-TA-Luc luciferase reporter plasmid which contains four E2F binding sites upstream
of TA promoter. Data shown as means ± SD of three independent experiments (Student t test, *p < 0.05).
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reduced luciferase activity (Figure 3G). These results
suggest that miR-188 downregulates CDK-mediated Rb
phosphorylation and subsequent activation of E2F.
MiR-188 directly binds to the 3′UTRs of target genes
To determine whether miR-188 indeed target CCND1,
CCND3, CCNA2, CCNE1, CDK2 and CDK4, we
employed luciferase reporter assay. The potential miR-
188 binding sequences within the 3′UTRs of target
genes were predicted by FindTar (Figure 4). The 3′UTR
fragments of target genes containing wild-type (WT) or
seed region mutated (Mu) of miR-188 binding sites were
inserted into a dual-luciferase reporter vector. When in-
troduced into cells, the wild-type 3′UTR reporters of
CCND1, CCND3, CCNA2, CCNE1, CDK2 and CDK4
exhibited a significant reduction of luciferase activity in
the miR-188 transfected cells as compared to control. In
contrast, the reporter vectors carrying seed mutated 3′
UTR fragments abrogated the inhibitory effect of miR-
188 on luciferase activity (Figure 4). Therefore, we con-
cluded that miR-188 inhibits target-gene expression
through direct interaction with their 3′UTRs.
MiR-188 suppresses tumor formation and progression in
nude mice
In order to determine the anti-cancer potential of miR-
188 in vivo, nude mice were injected with CNE cells
that stably expressed miR-188 or miR-NC. Strikingly,
tumor induction was dramatically prevented in miR-188
injected mice (Figure 5A). Tumor mass and tumor
volume were also significantly lower in mice injected
with miR-188 (Figure 5B and C). We then investigated
the expression of miR-188 targets in tumor tissues using
western blot. The protein levels of Cyclin E1, Cyclin D3,
Cyclin D1,Cyclin A2, CDK2 and CDK4 were significantly
decreased in tumor tissues harvested from miR-188
injected mice (Figure 5D and E). Compared with tumor
tissues from control mice, an obvious reduction of Rb
S811 and S780 phosphorylation was also detected in
miR-188 injected mice (Figure 5F and G). These results
provide strong evidence that miR-188 suppressestumor initiation and progression in vivo, potentially
through downregulation of multiple genes involved in
G1/S transition.
Discussion
Being capable of affecting multiple targets is one of the
most important feature of miRNAs. One miRNA can
regulate several targets in a signaling pathway, alterna-
tively, several miRNAs can also converge on a single tar-
get [13,14,26]. Co-regulation of a group of functionally
related genes to provoke detectable functional changes
is a common mode of miRNA-mediated gene regulation.
In this study, we demonstrate that miR-188 exerts
anti-cancer potential via downregulating multiple G1/S
related genes, including CCND1, CCND3, CCNE1,
CCNA2, CDK2 and CDK4. By suppressing the activation
of G1/S related Cyclin/CDKs, miR-188 suppresses Rb
phosphorylation and subsequent activation of E2F tran-
scription factor, which leads to G1/S cell cycle arrest and
growth inhibition in cancer cells (Figure 6).
Cell cycle is driven by the alternative expression or
degradation of different cyclins which exert their func-
tion by binding to different CDKs [19,40]. There are two
main groups of cyclins, G1/S Cyclins are essential for the
control of cell cycle at the G1/S transition, G2/M Cyclins
are essential for the control of cell cycle at G2/M transi-
tion and mitosis. Cyclin D is the first cyclin activated
by binding to CDK4/6 in the cell cycle progression. The
active Cyclin D/CDK4/6 complex phosphorylates Rb
protein [41]. The phosphorylated Rb dissociates from
Rb-E2F complex and activates E2F transcription factor.
E2F drives the expression of multiple genes that are
involved in regulating cell cycle progression, such as
CCNE, CCNA, DHFR, MYB and DNA polymerase, etc.
[42]. Cyclin E/CDK2 complex pushes cell cycle through
G1/S transition and Cyclin A/CDK2 complex drives cells
through S phase. A fundamental aspect of cancer is the
dysregulation of cell cycle control. Alterations in the
machinery that controls G1/S transition are frequently
observed in many types of human cancers [43-45].
For instance, amplification of CCND1 gene or overex-
pression of Cyclin D1 protein has been found in a
Figure 4 MiR-188 regulates target genes expression through direct binding to their 3′UTRs. Sequences of miR-188 and predicted
miR-188-binding sites at CCNA2, CCND1, CCND3, CCNE1, CDK2 and CDK4 3′UTRs. The mutant sequences (Mu) are identical to the wild-type (WT)
except the mutated nucleotides are shown in red. Luciferase vectors were generated by inserting WT or Mu 3′UTRs of target genes into pmirGLO
plasmid. The reporter vectors were co-transfected with miR-188 or miR-NC. Relative luciferase activity was determined at 24 h after transfection.
Results shown are means ± SD of three independent experiments (Student t test, **p < 0.01).
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CCND3 genes and their encoded proteins are also over-
expressed in many cancer cases in humans [47-51]. Hy-
peractivation of CDK4 or CDK6 is also found in several
human malignancies, which can be achieved through
deregulated expression of D-type Cyclins, or loss of CDK
inhibitor, p16INK4a [47,52-54]. Due to their critical role
in cell cycle progression and tumorigenesis, the Cyclin/
CDKs have been proposed as attractive therapeutic targets
for anti-cancer treatment.
Accelerated cell cycle progression is the common fea-
ture of most cancers. Several lines of evidence implicate
miRNAs as oncogenes or tumor suppressors through
directly modulating cell cycle machinery [55]. For in-
stance, the oncogenic miR-17/92 and miR-221/222 clus-
ters can downregulate CDK inhibitors and Rb family
members, leading to the activation of Cyclin/CDK com-
plexes and cell cycle progression [56-59]. On the other
hand, tumor suppressive miRNAs, such as let-7 and
miR-15 families, downregulate a wide spectrum of posi-
tive regulators of the cell cycle machinery [55]. Ourstudy provides strong evidence supporting miR-188 may
function as a tumor suppressor and it is a potential can-
didate for anti-cancer therapy.
Conclusions
Our data demonstrate a novel mechanism of miR-188
control on cell proliferation and cell cycle progression.
Through targeting multiple cyclin/CDK complexes, miR-
188 blocks G1/S transition, suppresses Rb phosphoryl-
ation and E2F transcriptional activity. The expression of
miR-188 also inversely correlates with expression of its
targets in NPC tissues. Moreover, miR-188 is capable of
inhibiting tumor initiation and progression in xenograft
mouse model, indicating that miR-188 may have anti-
cancer potential in human nasopharyngeal cancer.
Materials and methods
Cell culture and transfection
CNE cell line was purchased from Kunming Cell Bank
(China) and cultured in Dulbecco’s modified Eagle’s
medium (Gibco/Invitrogen, 12800–017) supplemented
Figure 5 MiR-188 suppresses tumor initiation and progression in vivo. (A) CNE cells stably expressing miR-188 or miR-NC were injected into
nude mice. MiR-188 (n = 12) suppressed tumorigenesis compared with miR-NC (n = 10). (B) miR-188 inhibits tumor growth in vivo. Tumor volumes
were calculated by the length and width measured by vernier calipers every 2 days. (C) The weight of tumors from mice from (B). miR-NC (mean:
327.9 mg; range: 39.6 to 659.4 mg); miR-188 (mean: 83.2 mg; range: 19.5 to 136.6 mg). (D) Immunoblot analysis of cyclin D1, cyclin D3, cyclin E1,
cyclin A2, CDK2, CDK4 and GAPDH in tumors treated with miR-NC or miR-188. (E) Relative protein expression was quantified by densitometric
analysis, GAPDH was used as internal control (Student t test, *p < 0.05). (F) Immunoblot analysis of phosphor-Rb Ser811, phosphor-Rb Ser780 and
total Rb in tumors treated with miR-NC or miR-188. (G) Relative Rb phosphorylation was quantified by densitometric analysis, total Rb was used
as internal control (Student t test, *p < 0.05).
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Figure 6 MiR-188 targets multiple genes involved in G1/S cell cycle transition. MiR-188 suppresses cyclin D/CDK4, cyclin E/CDK2 and cyclin
A/CDK2 activity by directly targeting their 3′UTRs. MiR-188 mediated downregulation of G1/S CDKs suppresses Rb phosphorylation and E2F
transcriptional activity, and finally leads to G1/S cell cycle arrest and growth inhibition.
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a humidified 5% CO2 incubator. Cells were transfected
with siRNA or miRNAs duplexes using Lipofectaime
2000 (Invitrogen Corp., Carlsbad, CA, USA) according
to manufacturer’s instructions. MiR-188 mimics and
miRNA inhibitors were synthesized and purified by
GenePharma Co. (Shanghai, China).
miRNA and mRNA expression
Total RNA from cultured cell were extracted with
RNAiso plus (Takara, 9108) following the manufacture’s
protocol. For miRNA expression assay, total RNA was
reversely transcribed using Taqman MicroRNA Reverse
Transcription Kit (Life Technologies, 4366597), then
miRNA real-time PCR was performed using Taqman
MicroRNA Assay Kit (Life Technologies). For mRNA
expression assay, total RNA was reversely transcribed
using M-MLV Reverse Transcription System (Takara)
and SYBE Green PCR master mix (Toyobo, QPK-201)
was purchased for mRNA real-time PCR. All quantita-
tive real-time PCR were performed on an ABI 7300 Real
Time System, RNU6 or GAPDH was used as internal
control for miRNA and mRNA assay respectively. Rela-
tive gene expression was calculated by mean of relative
quantification (2-ΔΔCt) as previously described [60]. The
specific real-time PCR primers for each gene were listed
in Table S2 (Additional file 5: Table S2).MiR-188 stable cell line
Plasmid carrying GFP and miR-188 hairpin was pur-
chased from GenePharma Co. (Shanghai, China). CNE
cells were transiently transfected with miR-188 plasmid,
followed by Blasticidin S (YEASEN, 60218ES10) selec-
tion at final concentration of 20 ug/ml. Stable clones
were obtained based on GFP expression.
Colony formation and cell proliferation assays
CNE cells were plated at a concentration of 3 × 103 cells
per well in 6-well plate and transfected with miR-188 or
miR-NC every three day after cells adhesion. MiR-NC or
miR-188 stable cells were plated at 4 × 103 cells per well
in 6-well plate. After culturing for 10 days, cells were
fixed with cold methanol and stained with 1% crystal
violet. The number of colonies was counted using Gel-
Pro analyzer software. For cell growth assay, cells were
plated at a concentration of 2 × 104 cells per well in 24-
well plate and transfected with miR-NC or miR-188, the
number of viable cells was determined by the trypan-
blue exclusion assay.
Bioinformatics analysis
In order to figure out the potential targets of miR-188,
we used Targetscan [61] (http://www.targetscan.org/)
and Findtar [62] (http://bio.sz.tsinghua.edu.cn/) algo-
rithm to search human genome based on NCBI mRNA
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targets were uploaded to DAVID Bioinformatics Re-
sources Functional Annotation Tool [38,39] (http://david.
abcc.ncifcrf.gov/home.jsp) for pathway annotation and
functional annotation clustering.
Western blotting
Cells were lysed in ice-cold whole cell lysis buffer
(50 mM Tris–HCl, pH 8.0, 4 M urea and 1% Triton X-
100) supplemented with complete protease inhibitor
Cocktail (Roche Diagnostics, 04693132001). Whole cell
lysates with equal protein were resolved by SDS-PAGE
and transferred to nitrocellulose membrane. After block-
ing with 5% milk in Tris-buffered saline plus 0.02%
Tween-20 (TBST), membranes were incubated with
the following antibodies: cyclin D1 (Epitomics, 1677–1),
cyclin D3 (Epitomics, 1846–1), E2F1 (Cell Signaling,
3742), cyclin E (Santa Cruz, sc-481), cyclin A (Santa
Cruz, sc-596), CDK2 (Cell Signaling, 2546), CDK4 (Cell
Signaling, 2906); phosphor-Rb (Ser 780) (Cell Signaling,
3590), phosphor-Rb (Ser-811) (ABclonal Biotechnology,
AP0089), total Rb (Cell Signaling, 9309) and GAPDH
(Proteintech, 10494-1-AP). Membranes were then incu-
bated with horseradish peroxidase-coupled specific sec-
ondary anti-mouse (KPL, 074–1806) or anti-rabbit antibodies
(KPL, 474–1506). Protein bands were visualized using
ECL blotting detection reagents (KPL, 54-61-00).
Clinical specimens
All nasopharyngeal carcinoma tissues were collected
from tumor resection in the Peking University Shenzhen
Hospital (Shenzhen, China). Informed consent was ob-
tained from each patient and this study was approved by
the local ethics committee.
Luciferase activity assay
The 3′ UTRs of CCND1, CCND3, CDK4, CCNA2, CDK2
and CCNE1 containing predicted targets of miR-188
and their corresponding mutants were amplified from re-
verse transcribed cDNA and cloned to pmirGLO Dual-
Luciferase reporter vector (Promega, E1330). The primer
sequences for the wild-type (WT) and mutated (Mu) con-
structs were listed in Table S3 (Additional file 5: Table S3).
For luciferase activity assay, WT or Mu constructs were
cotransfected with miR-NC or miR-188 into HeLa cell
using Lipofectamine 2000. Firefly and Renilla luciferase ac-
tivity were measured by Dual-Luciferase Reporter Assay
System (Promega, E1960). Relative luciferase activity was
calculated by normalization the ratio of firefly and Renilla
luciferase to that of negative control transfected cells. For
E2F activity assay, 200 ng of E2F reporter vector pE2F-
TA-Luc (Clontech, 63914) was cotransfected with miR-
NC or miR-188 into CNE cells [63]. Luciferase activity
was determined at 24 h after transfection.Cell synchronization and flow cytometry
For synchronization, cells transfected with miR-NC or
miR-188 were treated with 2 mM hydroxyurea (Sigma-
Aldrich, H8627) for 16 h to block cell at G1 phase. The
synchronized cells were released by washing the cells 3
times with pre-warmed PBS. At 6 h after release, the
cells were fixed in 70% ethanol in PBS overnight. Cells
were then stained with 10 μg/ml Propidium Iodide
(Sigma-Aldrich, P4170) for DNA content analysis by use
of a BD Influx™ Flow Cytometer (BD Biosciences).
BrdU Elisa assay
BrdU elisa assay was performed by use of a Cell prolifer-
ation Brdu Elisa Assay kit (Roche, 11647229001). CNE
cells transfected with indicated small RNAs were syn-
chronized at G1 phase by hydroxyurea treatment. Cells
were released and cultured with 10 μM BrdU for 2 h.
After removing labeling medium, cells were fixed and
incubated with anti-BrdU-POD working solution for
90 min. Cells were washed 3 times with washing solu-
tion and added substrate solution and incubated for 3–
10 min at room temperature. The incorporation of BrdU
during DNA synthesis in proliferating cells was deter-
mined by measuring the light emission of the samples in
a microplate luminometer.
EdU imaging assay
CNE cells transfected with indicated small RNAs were
synchronized at G1 phase by hydroxyurea treatment.
Cells were released and incubated with 25 μM EdU
and subsequently stained using a Click-iT EdU Alexa
Fluor 488 Imaging kit (Life Technologies, C10337). Im-
ages were taken with an Olympus FV1000 confocal
microscope (Olympus, Tokyo, Japan). The percentage
of cells labeled with EdU was quantified using Image
J software.
Tumor formation assay
Athymic nude mice aged 4 weeks were purchased from the
Experimental Animal Center of Guang Zhou University
of Chinese Medicine (Guang Zhou, China) and kept in
pathogen-free animal facilities for 2 weeks at Tsinghua
University Shenzhen Graduate School. All experimental
procedures involving animals were approved by the In-
stitutional Laboratory Animal Care and Use Committee
of Experimental Animal Center of Guang Zhou Univer-
sity of Chinese Medicine. Approximately 5 × 105 viable
CNE cells stably expressing miR-NC or miR-188 were
injected subcutaneously into the dorsal flank of nude
mice. Three weeks after tumor implantation, the mice
were sacrificed and the tumor incidence and tumor
weight of each animal was analyzed. The expression of
miR-188 target genes of each tumor was detected by
western blot.
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Data presented as bar graphs were the means ± S.D. of at
least three independent experiments. The student’s t test
was used to evaluate the significant difference between 2
groups of data. A P value less than 0.05 was considered
as statistically significant.Additional files
Additional file 1: Figure S1. The expression of miR-188 in CNE cells.
(A) The relative expression level of miR-188 in CNE cells transiently
transfected with miR-188 or miR-NC. (B) The relative expression level of
miR-188 in CNE cells stably expressing miR-188 or miR-NC (C1, clone 1;
C2, clone 2).
Additional file 2: Table S1. DAVID annotation categories the most
enrichment KEGG pathway. MAPK signaling pathway, ErbB signaling
pathway, Axon guidance and Cell cycle were the first four pathways
according to their p values.
Additional file 3: Figure S2. Densitometric analysis of miR-188 target
genes expression. (A) Relative protein levels of cyclin E1, CDK2, CDK4,
cyclin A2, cyclin D1 and cyclin D3 in CNE cells transiently transfected with
miR-NC or miR-188. (B) Relative protein levels of miR-188 targets in CNE
cells stably expressing miR-NC or miR-188 (C1, clone 1; C2, clone 2). (C)
Relative protein levels of miR-188 target genes in CNE cells transfected
with Ant-NC or Ant-199. GAPDH was used as internal control. Student
t test, *p < 0.05, **p < 0.01, ***p < 0.001.
Additional file 4: Figure S3. Stable expression of miR-188 inhibits G1/S
transition and Rb phosphorylation. (A) Flow Cytometry analysis of CNE
cells stably expressing miR-NC or miR-188 released from hydroxyurea
for 6 h. (B) Relative levels of Rb phosphorylation were quantified by
densitometric analysis. Total Rb was used as internal control. Student
t test, ** p < 0.01, ***p < 0.001. (C) Immunoblot analysis of phosphor-Rb
S811, phosphor-Rb S780, total Rb and GAPDH in CNE cells stably
expressing miR-NC or miR-188. (D) Relative levels of Rb phosphorylation
in (C) were quantified by densitometric analysis, total Rb was used as
internal control. Student t test, *p < 0.05, ** p < 0.01.
Additional file 5: Table S2 and Table S3. Primers used for qRT-PCR
(Table S2) and luciferase activity assay (Table S3).Abbreviations
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